VAT blow for haemophiliacs
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The parents of haemophiliac children who are demanding a purer and safer form of Factor VIII, received a setback to their campaign yesterday after a tribunal ruled that the blood product should be subject to VAT.
Genetically-engineered recombinant Factor VIII is now the treatment of choice for haemophiliacs, but it is more expensive than the plasma-derived version, and the decision to impose VAT will further discourage health authorities from purchasing it. The Haemophilia Society said it would appeal direct to the Chancellor to overturn the decision. Liz Hunt
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments